Even if only US shifts 20-30%, Indian API revenues could triple or quadruple in 10 years

Aditya Khemka says the US' Biosecure Act will benefit Pharma Cos like Piramal Pharma & Jubilant Pharmova which have mfg facilities in the US as they will be the first order beneficiary. Indian API exports are $4B while China's API exports are $40B. Even if only US shifts 20-30%, Indian API revenues could triple or quadruple in 10 years